Bottom line
GMOXX vs EMOP: the short answer
GMOXX (AB Government Money Market Portfolio) and EMOP (AB Emerging Markets Opportunities ETF) are both money market funds.
GMOXX is cheaper at 0.21% vs 0.7% — a difference of $49 a year per $10,000 invested.
Over five years, EMOP returned +4.6% a year vs +3.2% for GMOXX.
Updated Nov 19, 2026
GMOXX vs EMOP side by side
| GMOXX | EMOP | |
|---|---|---|
| Type | Money market fund | ETF |
| Fund family | Ab Fixed Income Shares | Ab Active Etfs |
| Category | Money Market | Emerging Markets |
| Expense ratio | 0.21% | 0.7% |
| Annual cost per $10k | $21 | $70 |
| 10-yr cost on $10k (prospectus) | $268 | — |
| Max front load | 0% | None |
| 12b-1 fee | 0% | 0% |
| 1-yr return | +4.2% | +30.7% |
| 5-yr return (annualized) | +3.2% | +4.6% |
| 10-yr return (annualized) | +2.1% | +7.4% |
| Best quarter | — | +21.9% |
| Worst quarter | — | −25.9% |
| Net assets (fund) | — | $2.1B |
| Number of holdings | — | 57 |
| Portfolio turnover | — | 79% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Holdings overlap
GMOXX and EMOP share none of their top holdings.
GMOXX top 10
EMOP top 10
- Taiwan Semiconductor Manufacturing Co Ltd — 17.14%
- Samsung Electronics Co Ltd — 10.63%
- SK hynix Inc — 8.10%
- ICICI Bank Ltd — 3.39%
- Delta Electronics Inc — 3.03%
- Fomento Economico Mexicano SAB de CV — 2.87%
- China Merchants Bank Co Ltd — 2.64%
- Petroleo Brasileiro SA - Petrobras — 2.63%
- Dr Reddy's Laboratories Ltd — 2.54%
- Colgate-Palmolive Co — 2.53%
FAQ
What is the difference between GMOXX and EMOP?
GMOXX (AB Government Money Market Portfolio) and EMOP (AB Emerging Markets Opportunities ETF) are both money market funds. GMOXX is cheaper at 0.21% vs 0.7% — a difference of $49 a year per $10,000 invested.
Which is cheaper, GMOXX or EMOP?
GMOXX has the lower expense ratio (0.21%).
Should I own both GMOXX and EMOP?
Because their portfolios differ, owning both can add diversification — check how they fit your overall allocation.
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.